您現在的位置 :
醫療團隊
專業的醫護人員,提供最佳的醫療服務
醫師介紹
TSENG, PO-LIN醫師
Hepatitis treatment including hepatitis B or C, autoimmune, and drug related hepatitis , liver cirrhosis, liver failure , liver dialysis , hepetocellular carcinoma biomarker and treatment , liver tumor radiogfrequency ablation, Wilson disease, gastrointestinal disease and diagnostic endoscope, inflammatory bowel disease
- Mandarin,English,Taiwanese
- Lecturer
醫師網路掛號
直接點選進入醫師網路掛號畫面
醫師資歷
-
學歷
- M.D., School of Medicine, Chang Gung University, Linkou, Taiwan.
- Ph.D., Graduate Institute of Clinical Medical Sciences, Chang Gung University, Linkou, Taiwan.
-
論文及期刊發表
- Fang HW#, Tseng PL#(co-first), Hu TH, Wang JH, Hung CH, Lu SN, Chen CH*. Hepatitis B relapse after entecavir or tenofovir alafenamide cessation under anti-viral prophylaxis for cancer chemotherapy. Virol J. 2024 Apr 3;21(1):79. (SCI)
B型肝炎癌症病人接受貝樂克或韋立得預防性用藥停藥後B型肝炎復發的比較 - Yang SY#, Hu TH#, Chou YP, Kuo YH, Tsai MC, Chang KC, Yen YH, Tseng PL*. Long-term comparisons of the durability of 6 months versus 12 months antiviral therapy for hepatitis B after chemotherapy cessation. J Infect Public Health. 2023 Nov;16(11):1852-1859. (SCI)
長期比較B型肝炎患者停止化學治療後延長六個月和十二個月抗病毒治療效果的持續性 - Tseng PL, Chen CW, Hu KH, Cheng HC, Lin YH, Tsai WH, Cheng TJ, Wu WH, Yeh CW, Lin CC, Tsai HJ, Chang HC, Chuang JH, Shan YS, Chang WT*. The decrease of glycolytic enzyme hexokinase 1 accelerates tumor malignancy via deregulating energy metabolism but sensitizes cancer cells to 2-deoxyglucose inhibition. Oncotarget. 2018 Apr 10;9(27):18949-18969. (SCI)
醣解酵素六碳糖激?表現減少經由改變能量代謝加速腫瘤惡性度但增加腫瘤細胞對2-DEOXYGLUCOSE抑制的敏感性 - Tseng PL, Wu WH, Hu TH, Chen CW, Cheng HC, Li CF, Tsai WH, Tsai HJ, Hsieh MC, Chuang JH, Chang WT*. Decreased succinate dehydrogenase B in human hepatocellular carcinoma accelerates tumor malignancy by inducing the Warburg effect. Sci Rep. 2018 Feb 15;8(1):3081. (SCI)
減少肝癌琥珀酸脫氫酉每乙型表現經由瓦氏效應加速腫瘤惡性度 - Tseng PL, Chen TC(co-first), Chien YS, Hung CH, Yen YH, Chang KC, Tsai MC, Lin MT, Lee CT, Shen CH, Hu TH*. Efficacy and safety of pegylated interferon alfa-2b and ribavirin combination therapy versus pegylated interferon monotherapy in hemodialysis patients: a comparison of 2 sequentially treated cohorts. Am J Kidney Dis. 2013 Oct;62(4):789-95. (SCI)
長效型干擾素ALFA-2B 合併雷巴威林與單用長效型干擾素ALFA-2B治療洗腎C型肝炎患者之效果及安全性 - Tseng PL, Wang JH, Hung CH, Tung HD, Chen TM, Huang WS, Liu SL, Hu TH, Lee CM, Lu SN*. Comparisons of noninvasive indices based on daily practice parameters for predicting liver cirrhosis in chronic hepatitis B and hepatitis C patients in hospital and community populations. Kaohsiung J Med Sci. 2013 Jul;29(7):385-95. (SCI)
比較日常使用參數組成的非侵入性指標來預測醫院或社區族群中慢性B型或C型肝炎造成的肝硬化 - Tseng PL, Wang JH, Tung HD, Hung CH, Kee KM, Chen CH, Chang KC, Lee CM, Changchien CS, Chen PF, Tsai LS, Lu SN*. Optimal treatment increased survival of hepatocellular carcinoma patients detected with community-based screening. J Gastroenterol Hepatol. 2010 Aug;25(8):1426-34. (SCI)
適當治療可以增加社區篩檢肝癌病患之存活 - Tseng PL, Tai MH, Huang CC, Wang CC, Lin JW, Hung CH, Chen CH, Wang JH, Lu SN, Lee CM, Changchien CS, Hu TH*. Overexpression of VEGF is associated with positive p53 immunostaining in hepatocellular carcinoma (HCC) and adverse outcome of HCC patients. J Surg Oncol. 2008 Oct 1;98(5):349-57. (SCI)
肝癌中之VEGF過度表現相關於P53表現,且預測不良預後。 - Tseng PL, Lu SN, Tung HD, Wang JH, Changchien CS, Lee CM*. Determinants of early mortality and benefits of lamivudine therapy in patients with hepatitis B virus-related decompensated liver cirrhosis. J Viral Hepat. 2005 Jul;12(4):386-92. (SCI)
B型肝炎相關肝硬化代償不全病患使用干安能之療效及早期死亡之決定因子
- Fang HW#, Tseng PL#(co-first), Hu TH, Wang JH, Hung CH, Lu SN, Chen CH*. Hepatitis B relapse after entecavir or tenofovir alafenamide cessation under anti-viral prophylaxis for cancer chemotherapy. Virol J. 2024 Apr 3;21(1):79. (SCI)